The 2023 Omnibus provides critical relief for labs and patients Washington, D.C. – The American Clinical Laboratory Association (ACLA) commends inclusion in the 2023 Omnibus Appropriations Bill … Read More
WASHINGTON, D.C. – The American Clinical Laboratory Association (ACLA) has launched the Stop Lab Cuts campaign, calling on Congress to protect patient access to laboratory services … Read More
Washington, D.C. – The American Clinical Laboratory Association (ACLA) today welcomed the bipartisan introduction of the Saving Access to Laboratory Services Act (SALSA) to ensure America’s seniors maintain … Read More
Copays are unfeasible for labs, shift the cost burden to vulnerable Medicare patients, and discourage early detection and prevention.
Self-referral leads to over-utilization, mistreated patients, and billions of wasted Medicare dollars. It’s time to close the loophole.
ACLA believes now is the appropriate time to develop a logical laboratory-developed test (LDT) framework that promotes innovation and advances patient care.
Medicare cuts to clinical labs threaten jobs, stifle innovation, and put patient access to vital lab tests at risk.
